Spectral CT in Radiotherapy for Cervical Cancer
The Clinical Research of Spectral CT in Radiotherapy for Cervical Cancer
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Fuquan Zhang, Porf
- Phone Number: 86 01069154072
- Email: zhangfq@pumch.cn
Study Locations
-
-
Beijing
-
Beijing, Beijing, China, 100010
- Recruiting
- Peking Union Medical College Hospital
-
Contact:
- Zheng Zeng, MD.
- Phone Number: 86 01069154073
- Email: zengzheng1206@163.com
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- All patients were confirmed cervical cancer by pathology
- patients were treated with concurrent chemoradiotherapy
- Spectral CT scans acquisition performed during the arterial phase and venous phase
- All the patients underwent a 18F-FDG PET/CT before treatment
Exclusion Criteria:
- CT without spectral scans
- History of allergy to intravenous contrast
- Pregnant or potentially pregnant female subjects
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Comparison of spectral CT derived data with response evaluation in cervical cancer
Time Frame: through study completion, an average of 2 year
|
To evaluate the tumor response of using quantitative parameters in spectral CT for cervical cancer patients according to RECIST 1.1
|
through study completion, an average of 2 year
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Identifying metastatic lymph nodes in cervical cancer with spectral CT
Time Frame: through study completion, an average of 2 year
|
To evaluate the diagnostic performances of using spectral CT for identifying metastatic lymph nodes in patients with cervical cancer
|
through study completion, an average of 2 year
|
|
Application of energy spectrum CT in brachytherapy of cervical cancer
Time Frame: through study completion, an average of 2 year
|
The ability to reduce metal artifact and assist in target delineation
|
through study completion, an average of 2 year
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms
- Urogenital Neoplasms
- Neoplasms by Site
- Uterine Neoplasms
- Genital Neoplasms, Female
- Uterine Cervical Diseases
- Uterine Diseases
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Urogenital Diseases
- Genital Diseases
- Genital Diseases, Female
- Uterine Cervical Neoplasms
Other Study ID Numbers
Other Study ID Numbers
- SPRTCC-Trial
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.